Maternal and Infant Syphilis Prevention Act

HR 3866, the Maternal and Infant Syphilis Prevention Act, requires the U.S. Department of Health and Human Services to issue federal guidance to states within 12 months. This guidance directs state Medicaid programs, Children's Health Insurance Programs (CHIP), and tribal health programs on improving syphilis screening for pregnant women - specifically emphasizing third-trimester and delivery testing - and expanding access to treatment. It also mandates best practices for provider education, telehealth integration, multilingual resources, and patient outreach to prevent congenital syphilis. The bill directly affects pregnant women, newborns, and healthcare providers operating under state health programs, aiming to reduce preventable infant deaths and health complications linked to untreated syphilis during pregnancy.